Announcements Trials
Browse Landscape

Phase

Phase 2 141Phase 3 61Phase 1 59Phase 1/2 56Phase 2/3 13Phase NA 4Phase EARLY_PHASE1 4Phase 4 3

Status

Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 4

Interventions

Standard of Care 176Blood Specimen Collection 135Exercise 121Educational Status 114Methods 108Interviews as Topic 106Surveys and Questionnaires 105Practice Guidelines as Topic 105Early Intervention, Educational 93Magnetic Resonance Spectroscopy 79Specimen Handling 78Radiosurgery 68Radiotherapy 54Palliative Care 48Biopsy 40Patient Navigation 37Control Groups 34Resistance Training 33Therapeutics 32Surgical Procedures, Operative 31Drug Therapy 31Diet Therapy 30Behavior Therapy 29Counseling 28Proton Therapy 25Acupuncture Therapy 25Nutrition Assessment 24Exercise Test 24Magnetic Resonance Imaging 23Health Promotion 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase NA × atezolizumab × 1 year × Clear all
NCT07543510 2026-04-22

Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma

Third Affiliated Hospital, Sun Yat-Sen University

Phase NA Not yet recruiting
38 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04180072 2026-04-09

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

National Health Research Institutes, Taiwan

Phase NA Active not recruiting
51 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07281664 2025-12-15

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Third Affiliated Hospital, Sun Yat-Sen University

Phase NA Not yet recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07272265 2025-12-09

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Sun Yat-sen University

Phase NA Completed
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡